Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the ...

GeoVax Labs' Mpox vaccine still has a long way to go before gaining approval or generating any type of revenue. Its treatment is still in pre-clinical development. That phase of development alone ...

Ethical Vaccine Development & Public Confidence – GeoVax embraces open regulatory processes, rigorous safety standards, and public access to data, ensuring confidence in its vaccines. These principles ...

Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum. ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE) - GeoVax Labs, ...

Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...

GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness. ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York und ...

Geovax Labs (NASDAQ:GOVX) just reported results for the second quarter of 2024. Geovax Labs reported earnings per share of -$1.99. This was above the analyst estimate for EPS of -$4.43.

GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The company’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.66. About GeoVax Labs ...

ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J.

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel ...